Be the first to like this
The pharmaceutical industry is experiencing various changes in the US biosimilars market. Pharmaceutical Research Analysts, Andrew Bourgoin and Beth Nuskey, Thomson Reuters investigates. The pharmaceutical industry is experiencing fundamental changes. On one side there is a drastic growth on global access to pharmaceuticals; on the other side we are seeing increased competition from emerging market players and a shift in the way drugs are being developed, manufactured, and delivered. One topic of these changes is the US biosimilars market. Biosimilar products offer competition to some of the most expensive drugs on the market, but also require high investment. This report will provide updates and changes associated with biosimilar regulations in the US. Additionally, will identify requirements for success, and the likely early entrants in the US market.